Target Price | $49.95 |
Price | $38.91 |
Potential | 28.38% |
Number of Estimates | 22 |
22 Analysts have issued a price target Baker Hughes 2026 . The average Baker Hughes target price is $49.95. This is 28.38% higher than the current stock price. The highest price target is $58.00 49.06% , the lowest is $40.00 2.80% . | |
A rating was issued by 28 analysts: 23 Analysts recommend Baker Hughes to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Baker Hughes stock has an average upside potential 2026 of 28.38% . Most analysts recommend the Baker Hughes stock at Purchase. |
21 Analysts have issued a sales forecast Baker Hughes 2025 . The average Baker Hughes sales estimate is $27.6b . This is 0.71% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $28.3b 1.84% , the lowest is $27.1b 2.78% .
This results in the following potential growth metrics:
2024 | $27.8b | 9.11% |
---|---|---|
2025 | $27.6b | 0.71% |
2026 | $28.5b | 3.30% |
2027 | $29.2b | 2.42% |
2028 | $29.1b | 0.52% |
2029 | $27.7b | 4.82% |
22 Analysts have issued an Baker Hughes EBITDA forecast 2025. The average Baker Hughes EBITDA estimate is $4.9b . This is 7.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.1b 12.13% , the lowest is $4.6b 2.88% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.5b | 21.22% |
---|---|---|
2025 | $4.9b | 7.87% |
2026 | $5.3b | 8.76% |
2027 | $5.6b | 5.95% |
2028 | $5.7b | 0.91% |
2029 | $5.3b | 7.26% |
2024 | 16.23% | 11.10% |
---|---|---|
2025 | 17.64% | 8.66% |
2026 | 18.57% | 5.27% |
2027 | 19.21% | 3.45% |
2028 | 19.49% | 1.46% |
2029 | 18.99% | 2.57% |
10 Baker Hughes Analysts have issued a net profit forecast 2025. The average Baker Hughes net profit estimate is $2.5b . This is 13.88% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.6b 10.40% , the lowest is $2.4b 17.45% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.9b | 56.02% |
---|---|---|
2025 | $2.5b | 13.88% |
2026 | $2.9b | 14.02% |
2027 | $3.2b | 10.13% |
2024 | 10.60% | 43.00% |
---|---|---|
2025 | 9.19% | 13.28% |
2026 | 10.15% | 10.45% |
2027 | 10.91% | 7.49% |
10 Analysts have issued a Baker Hughes forecast for earnings per share. The average Baker Hughes EPS is $2.57 . This is 13.76% lower than earnings per share in the financial year 2024. The highest EPS forecast is $2.67 10.40% , the lowest is $2.46 17.45% .
This results in the following potential growth metrics and future valuations:
2024 | $2.98 | 56.02% |
---|---|---|
2025 | $2.57 | 13.76% |
2026 | $2.93 | 14.01% |
2027 | $3.22 | 9.90% |
Current | 13.06 | 24.38% |
---|---|---|
2025 | 15.16 | 16.08% |
2026 | 13.30 | 12.27% |
2027 | 12.07 | 9.25% |
Based on analysts' sales estimates for 2025, the Baker Hughes stock is valued at an EV/Sales of 1.47 and an P/S ratio of 1.39 .
This results in the following potential growth metrics and future valuations:
Current | 1.46 | 2.82% |
---|---|---|
2025 | 1.47 | 1.00% |
2026 | 1.43 | 3.19% |
2027 | 1.39 | 2.36% |
2028 | 1.40 | 0.52% |
2029 | 1.47 | 5.06% |
Current | 1.38 | 6.77% |
---|---|---|
2025 | 1.39 | 0.72% |
2026 | 1.35 | 3.20% |
2027 | 1.32 | 2.36% |
2028 | 1.33 | 0.52% |
2029 | 1.39 | 5.06% |
Analyst | Rating | Action | Date |
---|---|---|---|
Stifel |
Buy
➜
Buy
|
Unchanged | Apr 15 2025 |
Susquehanna |
Positive
➜
Positive
|
Unchanged | Apr 14 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Apr 08 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Mar 31 2025 |
Benchmark |
Buy
➜
Buy
|
Unchanged | Feb 11 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 04 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Feb 03 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Stifel:
Buy
➜
Buy
|
Apr 15 2025 |
Unchanged
Susquehanna:
Positive
➜
Positive
|
Apr 14 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Apr 08 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Mar 31 2025 |
Unchanged
Benchmark:
Buy
➜
Buy
|
Feb 11 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 04 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Feb 03 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.